Methods and compositions involving p62 / sqstm1 for the treatment and prevention of inflammation-related diseases
By applying p62/SQSTM1 peptide to regulate pro-inflammatory cytokines and bone metabolism factors, the problem of poor efficacy of existing anti-inflammatory drugs in the treatment of chronic inflammatory diseases has been solved, achieving effective treatment and prevention of chronic inflammatory diseases.
CN122399002APending Publication Date: 2026-07-17CURELAB ONCOLOGY INC
View PDF 9 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- CURELAB ONCOLOGY INC
- Filing Date
- 2014-12-29
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing anti-inflammatory drugs are not very effective in treating chronic inflammatory diseases and have side effects, and there is no effective treatment for chronic inflammation.
Method used
By administering p62/SQSTM1 peptide or its variants, the expression of pro-inflammatory cytokines, osteogenic transcription factors, and bone resorption factors is modulated in subjects, and agents of p62/SQSTM1 peptide or its variants are used to treat and prevent chronic inflammatory diseases.
Benefits of technology
It effectively regulates inflammatory responses, reduces or prevents symptoms of chronic inflammatory diseases, including osteoporosis, obesity, and type 2 diabetes, and lowers morbidity and reduces drug side effects.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122399002A_ABST
Abstract
本发明提供一种用于促炎细胞因子、成骨转录因子、骨吸收因子以及内源性p62表达调节的新型p62组合物。因而，这样的p62组合物适用于炎症性疾病的预防和治疗，并且本发明还提供了相关方法。在某些实施例中，炎症性疾病与癌症不相关。在一些实施方式中，炎症性疾病包括，但不限于，骨质疏松症、肥胖症、代谢综合征、2型糖尿病、脂肪肝、炎症性肠道疾病、慢性胰腺炎、哮喘、慢性阻塞性肺病（COPD）、类风湿性关节炎（RA）、骨关节炎、多发性硬化症（MS）、银屑病、充血性心力衰竭（CHF）、动脉粥样硬化、神经退行性疾病（ALS，帕金森症、阿尔兹海默症、亨廷顿病）、抑郁症、精神分裂症、痛风、石棉肺以及矽肺。
Need to check novelty before this filing date? Find Prior Art